Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel combinations with oxaliplatin.

S Mani1, J Manalo, D Bregman

  • 1Department of Medicine and Oncology, Montefiore Medical Center, Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA. smani@montefiore.org

Oncology (Williston Park, N.Y.)
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormonal stimulation reduces numbers and impairs function of human uterine natural killer cells during implantation.

Human reproduction (Oxford, England)·2023
Same author

Potential antiviral effects of pantethine against SARS-CoV-2.

Scientific reports·2023
Same author

Urinary Ascites and Transient Intestinal Obstruction in a Preterm Infant: An Interesting Case of Posterior Urethral Valve.

AJP reports·2019
Same author

<i>REPLY</i>.

AJNR. American journal of neuroradiology·2018
Same author

Brain Imaging in Cases with Positive Serology for Dengue with Neurologic Symptoms: A Clinicoradiologic Correlation.

AJNR. American journal of neuroradiology·2018
Same author

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

International journal of laboratory hematology·2016
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Oxaliplatin is a platinum-based chemotherapy drug effective against colorectal cancer. This review explores novel drug combinations with oxaliplatin for enhanced cancer treatment efficacy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Oxaliplatin is a platinum derivative with cytotoxic effects, inhibiting DNA replication and transcription.
  • It demonstrates higher potency and efficacy than cisplatin and carboplatin in preclinical models, including cisplatin-resistant cell lines.
  • Oxaliplatin is approved for metastatic colorectal cancer treatment in combination with fluoropyrimidines in several regions.

Purpose of the Study:

  • To review published literature on novel combination therapies involving oxaliplatin.
  • To highlight preclinical and clinical data on oxaliplatin combined with new therapeutic agents.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of combination therapies with thymidylate synthase inhibitors, EGFR antagonists, and microtubule agents.

Related Experiment Videos

Main Results:

  • Oxaliplatin shows broad efficacy across various solid tumors.
  • Preclinical data suggest promising results for combination therapies with novel agents.

Conclusions:

  • Oxaliplatin is a valuable agent in cancer treatment, particularly for colorectal cancer.
  • Further research into novel combinations holds potential for improved therapeutic outcomes.